Perspectives for immunotherapy in noninfectious immune mediated uveitis

References

• Leclercq M, Desbois A-C, Domont F, et al. Biotherapies in Uveitis. J Clin Med. 2020;9(11):3599.
   Web of Science ®Google Scholar
• Prete M, Dammacco R, Fatone MC, et al. Autoimmune uveitis: clinical, pathogenetic, and therapeutic features. Clin Exp Med. 2016;16(2):125–136.
   PubMed Web of Science ®Google Scholar
• Touhami S, Diwo E, Sève P, et al. Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opin Biol Ther. 2019;19(5):477–490.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Gangaputra S, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the systemic immunosuppressive therapy for eye diseases (SITE) cohort study. Ophthalmic Epidemiol. 2008;15(1):47–55.
   PubMed Web of Science ®Google Scholar
• Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–432.e1-2.
   PubMed Web of Science ®Google Scholar
• Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(2188–2198.e1):2188–2198.e1.
   PubMedGoogle Scholar
• Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(500–509.e2):500–509.e2.
   Google Scholar
• Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115(10):1826–1832.
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014;121(10):1863–1870.
   PubMed Web of Science ®Google Scholar
• Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatol Oxf Engl. 2013;52(5):825–831.
   PubMed Web of Science ®Google Scholar
• Kostik MM, Gaidar EV, Hynnes AY, et al. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. Clin Exp Rheumatol. 2016;34:714–718.
   PubMed Web of Science ®Google Scholar
• Sardar E, Dusser P, Rousseau A, et al. Retrospective study evaluating treatment decisions and outcomes of childhood uveitis not associated with juvenile idiopathic arthritis. J Pediatr. 2017;186:131–137.
   PubMed Web of Science ®Google Scholar
• Henderson LA, Zurakowski D, Angeles-Han ST, et al. Medication use in juvenile uveitis patients enrolled in the Childhood arthritis and rheumatology research alliance registry. Pediatr Rheumatol Online J. 2016;14(1):9.
   PubMedGoogle Scholar
• Kalinina Ayuso V, van de Winkel EL, Rothova A, et al. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol. 2011;151(2):217–222.
   PubMed Web of Science ®Google Scholar
• Diedrichs-Möhring M, Kaufmann U, Wildner G. The immunopathogenesis of chronic and relapsing autoimmune uveitis - Lessons from experimental rat models. Prog Retin Eye Res. 2018;65:107–126.
   PubMed Web of Science ®Google Scholar
• Valentincic NV, de Groot-Mijnes JDF, Kraut A, et al. Intraocular and serum cytokine profiles in patients with intermediate uveitis. Mol Vis. 2011;17:2003–2010.
   PubMed Web of Science ®Google Scholar
• Ama E-A, Struyf S, Kangave D, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol Orlando Fla. 2011;139(2):177–184.
   PubMed Web of Science ®Google Scholar
• Atan D, Fraser-Bell S, Plskova J, et al. Cytokine polymorphism in noninfectious uveitis. Invest Ophthalmol Vis Sci. 2010;51(8):4133–4142.
   PubMed Web of Science ®Google Scholar
• Evereklioglu C, Er H, Türköz Y, et al. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s disease. Mediators Inflamm. 2002;11(2):87–93.
   PubMed Web of Science ®Google Scholar
• Falvo JV, Tsytsykova AV, Goldfeld AE. Transcriptional control of the TNF gene. Curr Dir Autoimmun. 2010;11:27–60.
   PubMedGoogle Scholar
• Tsai EY, Yie J, Thanos D, et al. Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. Mol Cell Biol. 1996;16:5232–5244.
   PubMed Web of Science ®Google Scholar
• Dick AD, Forrester JV, Liversidge J, et al. The role of tumour necrosis factor (TNF-α) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004;23(6):617–637.
   PubMed Web of Science ®Google Scholar
• Welser-Alves JV, Milner R. Microglia are the major source of TNF-α and TGF-β1 in postnatal glial cultures; regulation by cytokines, lipopolysaccharide, and vitronectin. Neurochem Int. 2013;63(1):47–53.
   PubMed Web of Science ®Google Scholar
• Masli S, Sheibani N, Cursiefen C, et al. Matricellular protein thrombospondins: influence on ocular angiogenesis, wound healing and immuneregulation. Curr Eye Res. 2014;39(8):759–774.
   PubMed Web of Science ®Google Scholar
• Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol. 2004;36(6):961–968.
   PubMed Web of Science ®Google Scholar
• Pimanda JE, Annis DS, Raftery M, et al. The von Willebrand factor-reducing activity of thrombospondin-1 is located in the calcium-binding/C-terminal sequence and requires a free thiol at position 974. Blood. 2002;100(8):2832–2838.
   PubMed Web of Science ®Google Scholar
• Asch AS, Liu I, Briccetti FM, et al. Analysis of CD36 binding domains: ligand specificity controlled by dephosphorylation of an ectodomain. Science. 1993;262(5138):1436–1440.
   PubMed Web of Science ®Google Scholar
• Shalaby MR, Waage A, Aarden L, et al. Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo. Clin Immunol Immunopathol. 1989;53(3):488–498.
   PubMedGoogle Scholar
• Zhang YH, Lin JX, Yip YK, et al. Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: role in the induction of interleukin 6. Proc Natl Acad Sci U S A. 1988;85(18):6802–6805.
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33(5):251–255.
   PubMed Web of Science ®Google Scholar
• Touhami S, Beguier F, Augustin S, et al. Chronic exposure to tumor necrosis factor alpha induces retinal pigment epithelium cell dedifferentiation. J Neuroinflammation. 2018;15(1):85.
   PubMedGoogle Scholar
• Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol Chic III 1960. 2003;Vol. 121(4):437–440.
   PubMed Web of Science ®Google Scholar
• Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65(12):1631–1634.
   PubMed Web of Science ®Google Scholar
• Lie E, Lindström U, Zverkova-Sandström T, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis. 2017;76(9):1515–1521.
   PubMed Web of Science ®Google Scholar
• Wendling D, Joshi A, Reilly P, et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin. 2014;30(12):2515–2521.
   PubMed Web of Science ®Google Scholar
• Leal I, Rodrigues FB, Sousa DC, et al. Anti-TNF drugs for chronic uveitis in adults-a systematic review and meta-analysis of randomized controlled trials. Front Med. 2019;6:104.
   PubMed Web of Science ®Google Scholar
• Maccora I, Fusco E, Marrani E, et al. Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis. Rheumatol Oxf Engl. 2021;60(2):568–587.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Bodaghi B, Bienvenu B, et al. Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies. Autoimmun Rev. 2013;12(7):774–783.
   PubMed Web of Science ®Google Scholar
• Li B, Li H, Zhang L, et al. Efficacy and safety of adalimumab in noninfectious uveitis: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2021;12:673984.
   PubMed Web of Science ®Google Scholar
• JaffeGJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis.N Engl JMed. 2016;375(10):932–943.
   PubMed Web of Science ®Google Scholar
• SheppardJ, Joshi A, Betts KA, et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 Trials. JAMA Ophthalmol. 2017;135:511–518.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet Lond Engl. 2016;388(10050):1183–1192.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Adán A, Brézin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125(7):1075–1087.
   PubMed Web of Science ®Google Scholar
• Díaz-Llopis M, Salom D, Garcia-de-vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119(8):1575–1581.
   PubMed Web of Science ®Google Scholar
• Vallet H, Seve P, Biard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network. Arthritis Rheumatol Hoboken NJ. 2016;68(6):1522–1530.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. Clin Rheumatol. 2019 Jan;38(1):63-70.
   Google Scholar
• Fabiani C, Sota J, Vitale A, et al. Cumulative retention rate of adalimumab in patients with Behçet’s disease-related uveitis: a four-year follow-up study. Br J Ophthalmol. 2018;102(5):637–641.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet’s disease: national multicenter study of 177 cases. Arthritis Rheumatol Hoboken NJ. 2019;71(12):2081–2089.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637–1646.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Benton D, et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials. 2014;15(1):14.
   PubMedGoogle Scholar
• Horton S, Jones AP, Guly CM, et al. Adalimumab in juvenile idiopathic arthritis-associated Uveitis: 5-year follow-up of the Bristol participants of the SYCAMORE trial. Am J Ophthalmol. 2019;207:170–174.
   PubMed Web of Science ®Google Scholar
• Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018 Jul;77(7):1003-1011.
   Google Scholar
• Ho M, Chen LJ, Sin HPY, et al. Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet’s disease-related uveitis. J Ophthalmic Inflamm Infect. 2019;9(1):14.
   PubMedGoogle Scholar
• Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol Chic Ill. 1960;2009(127):819–822.
   Google Scholar
• Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and efficacy of infliximab therapy in active behcet’s uveitis: an open-label trial. Rheumatol Int. 2008;29(1):53–57.
   PubMed Web of Science ®Google Scholar
• De Simone L, Invernizzi A, Aldigeri R, et al. Effectiveness of infliximab and interferon alpha-2a for the treatment of behçet’s uveitis: customizing therapy according to the clinical features. Ocul Immunol Inflamm. 2020 Oct 6;1–9.
   Google Scholar
• Lejoyeux R, Diwo E, Vallet H, et al. INFLIXIMAB and ADALIMUMAB in Uveitic Macular Edema. Ocul Immunol Inflamm. 2018;26(7):991–996.
   PubMed Web of Science ®Google Scholar
• Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67–74.
   PubMed Web of Science ®Google Scholar
• Kunimi K, Usui Y, Asakage M, et al. Anti-TNF-α therapy for refractory uveitis associated with Behçet’s syndrome and sarcoidosis: a single center study of 131 patients. Ocul Immunol Inflamm. 2020;1–8.
   Web of Science ®Google Scholar
• Protocole National de Diagnostic et de Soins sur la Maladie de Behçet. [(accessed on 2020 Sept 14)]; Available online: https://www.has-sante.fr/upload/docs/application/pdf/2020-01/pnds_behcet_vf_171219.pdf.
   Google Scholar
• Hatemi G, Christensen R, Bang D, et al. update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;2018(77):808–818.
   Google Scholar
• Ohno S, Umebayashi I, Matsukawa M, et al. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet’s disease: a large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther [Internet]. 2019 [cited 2021 Feb 28];21. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321670/.
   Google Scholar
• Calvo-Río V, Blanco R, Santos-Gómez M, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016;46(1):95–101.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Rigante D, et al. Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with behçet’s disease. Ocul Immunol Inflamm. 2019;27(1):58–63.
   PubMed Web of Science ®Google Scholar
• Tosi GM, Sota J, Vitale A, et al. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin Exp Rheumatol. 2019;37:680–683.
   PubMed Web of Science ®Google Scholar
• van der Horst-Bruinsma I, van Bentum R, Verbraak FD, et al. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW. RMD Open. 2020;6(1):e001161.
   Web of Science ®Google Scholar
• Sharon Y, Chu DS. Certolizumab pegol - Tumor necrosis factor inhibitor for refractory uveitis. Am J Ophthalmol Case Rep. 2020;18:100633.
   PubMedGoogle Scholar
• Prieto-Peña D, Calderón-Goercke M, Adán A, et al. Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. Clin Exp Rheumatol. 2021;39:105–114.
   PubMed Web of Science ®Google Scholar
• Acharya NR, Ebert CD, Kelly NK, et al. Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial. Trials. 2020;21(1):887.
   PubMed Web of Science ®Google Scholar
• Galor A, Perez VL, Hammel JP, et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113(12):2317–2323.
   PubMed Web of Science ®Google Scholar
• Sukumaran S, Marzan K, Shaham B, et al. High dose infliximab in the treatment of refractory uveitis: does dose matter? ISRN Rheumatol. 2012;2012:765380.
   PubMedGoogle Scholar
• Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study. Ophthalmology. 2014;121(10):1877–1884.
   PubMed Web of Science ®Google Scholar
• Lee J, Koreishi AF, Zumpf KB, et al. Success of weekly adalimumab in refractory ocular inflammatory disease. Ophthalmology. 2020;127(10):1431–1433.
   PubMed Web of Science ®Google Scholar
• Liberman P, Berkenstock MK, Burkholder BM, et al. Escalation to Weekly Adalimumab for the Treatment of Ocular Inflammation. Ocul Immunol Inflamm. 2020 May 14;1–5.
   Google Scholar
• Silpa-Archa S, Oray M, Preble JM, et al. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol (Copenh). 2016;94(6):e400–406.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol Hoboken NJ. 2017;69(3):668–675.
   PubMed Web of Science ®Google Scholar
• Kuryltsiv NB, Halei KM. The role of interleukins and their inhibitors in the development of autoimmune uveitis. Wiad Lek. 2019;72(4):716–722.
   PubMedGoogle Scholar
• Karkhur S, Hasanreisoglu M, Vigil E, et al. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. J Ophthalmic Inflamm Infect. 2019;9(1):17.
   PubMed Web of Science ®Google Scholar
• Sepah YJ, Sadiq MA, Chu DS, et al. Primary (month-6) outcomes of the stop-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71–80.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020;2(3):e135–e141.
   PubMedGoogle Scholar
• S L. Tocilizumab: a Review in Rheumatoid Arthritis. Drugs [Internet]. 2017 [cited 2021 Jun 16];77. Available from: https://pubmed.ncbi.nlm.nih.gov/29094311/
   Google Scholar
• Atienza-Mateo B, Calvo-Río V, Beltrán E, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet’s disease: multicentre retrospective study. Rheumatol Oxf Engl. 2018;57(5):856–864.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Zierhut M, Igney-Oertel A, et al. Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment. Ocul Immunol Inflamm. 2017;25(2):215–220.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenç V, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018 Jul;38(7):1361-1370.
   Google Scholar
• Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the Phase 2 SATURN study. Ophthalmology. 2019;126(3):428–437.
   PubMed Web of Science ®Google Scholar
• Sota J, Rigante D, Lopalco G, et al. Biological therapies for the treatment of Behçet’s disease-related uveitis beyond TNF-alpha blockade: a narrative review. Rheumatol Int. 2018;38(1):25–35.
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–787.
   PubMed Web of Science ®Google Scholar
• Letko E, Yeh S, Foster CS, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122(5):939–948.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191–197.
   PubMed Web of Science ®Google Scholar
• Brambilla A, Caputo R, Cimaz R, et al. Canakinumab for childhood sight-threatening refractory uveitis: a case series. J Rheumatol. 2016;43(7):1445–1447.
   PubMed Web of Science ®Google Scholar
• Simonini G, Xu Z, Caputo R, et al. Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum. 2013;65(2):513–518.
   PubMed Web of Science ®Google Scholar
• Pepple KL, Lin P. Targeting interleukin-23 in the treatment of noninfectious uveitis. Ophthalmology. 2018;125(12):1977–1983.
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Atzori L, Del Piano M, et al. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. Dermatol Ther. 2017;30(5).
   Web of Science ®Google Scholar
• Chateau T, Angioi K, Two P-BL. Cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn’s disease. J Crohns Colitis. 2020;14(4):571.
   PubMed Web of Science ®Google Scholar
• Guillo L, D’Amico F, Danese S, et al. Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review. J Crohn's Colitis. 2021 Jul 5;15(7):1236-1243.
   Google Scholar
• Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146(837–844.e1):837–844.e1.
   PubMedGoogle Scholar
• Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades-Behçet’s disease treated with interferon-alpha-2a. J Rheumatol. 2008;35:896–903.
   PubMed Web of Science ®Google Scholar
• Fardeau C, Simon A, Rodde B, et al. Interferon-alpha2a and systemic corticosteroid in monotherapy in chronic uveitis: results of the randomized controlled birdferon study. Am J Ophthalmol. 2017;177:182–194.
   PubMed Web of Science ®Google Scholar
• Mackensen F, Jakob E, Springer C, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol. 2013;156(478–486.e1):478–486.e1.
   PubMedGoogle Scholar
• Doycheva D, Zierhut M, Blumenstock G, et al. Mycophenolate mofetil in the therapy of uveitic macular edema–long-term results. Ocul Immunol Inflamm. 2012;20(3):203–211.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Kötter I, Günaydin I, et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93(7):906–913.
   PubMed Web of Science ®Google Scholar
• Diwo E, Gueudry J, Saadoun D, et al. Long-term efficacy of interferon in severe uveitis associated with Behçet disease. Ocul Immunol Inflamm. 2017;25(1):76–84.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13(3):246–252.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Dheyab A, Khatib D, et al. Efficacy of B cell depletion therapy with rituximab in refractory chronic recurrent uveitis associated with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2020;1–8. https://doi.org/10.1080/09273948.2020.1820531.
   PubMed Web of Science ®Google Scholar
• Willis MD, Pickersgill TP, Robertson NP, et al. Alemtuzumab-induced remission of multiple sclerosis-associated uveitis. Int Ophthalmol. 2017;37(5):1229–1233.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Smith RM, Chow YW, et al. Alemtuzumab as remission induction therapy in Behçet disease: a 20-year experience. J Rheumatol. 2015;42(10):1906–1913.
   PubMed Web of Science ®Google Scholar
• Menean M, Marchese A, Bordato A, et al. Bilateral acute retinal necrosis during treatment with alemtuzumab for multiple sclerosis. Eur J Ophthalmol. 2021;11206721211006576.
   Web of Science ®Google Scholar
• Paley MA, Karacal H, Rao PK, et al. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2019;13:53–55.
   PubMedGoogle Scholar
• Bauermann P, Heiligenhaus A, Heinz C. Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2019;27(8):1232–1234.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Giuffrè C, Cornalba M, et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39:847–851.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behçet’s syndrome–a phase 2, placebo-controlled study. N Engl J Med. 2015;372:1510–1518.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of apremilast for oral ulcers in Behçet’s syndrome. N Engl J Med. 2019;381:1918–1928.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Martín-Varillas JL, Graña J, et al. Apremilast in refractory orogenital ulcers and other manifestations of Behçet’s disease. A national multicentre study of 51 cases in clinical practice. Clin Exp Rheumatol. 2020;38(Suppl 127):69–75.
   PubMedGoogle Scholar
• Chen Y, Li Z, Li H, et al. Apremilast regulates the teff/treg balance to ameliorate uveitis via PI3K/AKT/FoxO1 Signaling pathway. Front Immunol. 2020;11:581673.
   PubMed Web of Science ®Google Scholar